

Application No.: 09/782,587
Attorney Docket No: 0212us310
Page 2 of 17

Listing of Claims:

The following listing of claims replaces all prior versions and listings of claims in the application. Additions are indicated by underlining and deletions are indicated by ~~strike through~~.

1. - 67. (Canceled)

68. (Currently Amended) A conjugate comprising:

a polypeptide comprising an amino acid sequence which (a) differs from the hFVII or hFVIIa sequence SEQ ID NO:1 in 1-15 amino acid residues and (b) comprises an introduced *in vivo* N-glycosylation site relative to SEQ ID NO:1, wherein the introduced *in vivo* N-glycosylation site comprises a the substitution selected from the group consisting of T106N; I205S/T, V253N, T267N, and R315N+V317S/T; and

a sugar moiety covalently attached to the introduced *in vivo* N-glycosylation site, wherein the conjugate exhibits at least 25% of the clotting activity of hFVIIa.

69. (Currently Amended) The conjugate of claim 68, further comprising at least one additional ~~two or more said~~ introduced *in vivo* N-glycosylation sites.

70 - 74. (Canceled)

75. (Previously Presented) The conjugate of claim 69, comprising the substitutions T106N and I205S/T.

76. (Previously Presented) The conjugate of claim 69, comprising the substitutions T106N and V253N.

77. (Previously Presented) The conjugate of claim 69, comprising the substitutions T106N and R315N+V317S/T.

Application No.: 09/782,587
Attorney Docket No: 0212us310
Page 3 of 17

78. – 80. (Canceled)

81. (Previously Presented) The conjugate of claim 69, comprising the substitutions T106N, I205S/T, and V253N.

82. (Previously Presented) The conjugate of claim 69, comprising the substitutions T106N, I205S/T, and T267N.

83. (Previously Presented) The conjugate of claim 69, comprising the substitutions T106N, V253N, and T267N.

84. – 85. (Canceled)

86. (Currently Amended) The conjugate of claim 8569, wherein the additional introduced *in vivo* N-glycosylation site is introduced in a position relative to SEQ ID NO:1 occupied by an amino acid residue with more than 25% of its side chain exposed to the solvent.

87. (Currently Amended) The conjugate of claim 8569, wherein the additional introduced *in vivo* N-glycosylation site comprises an amino acid substitution in a position selected from the group consisting of 28-48, 139-147, 286-294, 311-319, 338-345 and 388-406 relative to SEQ ID NO:1.

88. (Previously Presented) The conjugate of claim 68, further comprising at least one non-polypeptide moiety covalently attached to an amino acid residue of the polypeptide, wherein the non-polypeptide moiety is different from a sugar moiety.

89. (Previously Presented) The conjugate of claim 88, wherein the non-polypeptide moiety is a polymer molecule.

Application No.: 09/782,587
Attorney Docket No: 0212us310
Page 4 of 17

90. (Currently Amended) The conjugate of claim 8289, wherein the polymer molecule is a linear polyethylene glycol or a branched polyethylene glycol.

91. (Previously Presented) The conjugate of claim 68, exhibiting at least 10% of the catalytic activity of hFVIIa.

92. (Canceled)

93. (Currently Amended) A polypeptide comprising the amino acid sequence of claim 68, exhibiting at least 25% of the clotting activity of hFVIIa.

94. (Previously Presented) The polypeptide of claim 93, exhibiting at least 10% of the catalytic activity of hFVIIa.

95. – 102. (Canceled)

103. (Previously Presented) A composition comprising the conjugate of claim 68 and a pharmaceutically acceptable carrier or excipient.

104. (Previously Presented) The composition of claim 103, wherein the composition is an aqueous solution.

105. (Previously Presented) The composition of claim 103, comprising a buffering agent.

106. (Withdrawn) A method for increasing blood clot formation in a mammal with a disease or condition in which increased clot formation is desirable, comprising administering to the mammal an amount of the conjugate of claim 68 effective to increase blood clot formation.

Application No.: 09/782,587
Attorney Docket No: 0212us310
Page 5 of 17

107. (Withdrawn) The method of claim 106, wherein the disease or condition is associated with severe tissue damage.

108. (Withdrawn) The method of claim 106 wherein the disease or condition is associated with trauma.

109. (Withdrawn) The method of claim 106, wherein the disease or condition is associated with major surgery.

110. (Withdrawn) The method of claim 106, wherein the disease or condition is hemophilia or thrombocytopenia.

111. (Withdrawn) A method for preparing a composition, comprising mixing the conjugate of claim 68 with a pharmaceutically acceptable carrier or excipient.

112. (Withdrawn) The method of claim 111, wherein the pharmaceutically acceptable excipient comprises a buffering agent.

113. -116. (Canceled)